EP 4171232 A1 20230503 - MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE
Title (en)
MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE
Title (de)
FORMULIERUNGEN MIT MODIFIZIERTER FREISETZUNG VON MODIFIZIERTEN FORMEN VON TRIMETAZIDIN
Title (fr)
FORMULATIONS À LIBÉRATION MODIFIÉE DE FORMES MODIFIÉES DE TRIMÉTAZIDINE
Publication
Application
Priority
- US 202063046115 P 20200630
- US 202063046117 P 20200630
- US 202163183294 P 20210503
- US 202163183299 P 20210503
- US 2021039303 W 20210628
Abstract (en)
[origin: WO2022005926A1] The invention provides pharmaceutical compositions that contain modified release formulations of modified forms of trimetazidine, such as CV-8972. The compositions include an erodible polymer, such as hydroxypropyl methylcellulose (HPMC), that allows sustained release of the modified form of trimetazidine and it metabolic products in the body. The invention also provides methods of treating conditions, including angina and heart failure, using such compositions.
IPC 8 full level
A01N 43/04 (2006.01); A61K 31/675 (2006.01); A61K 39/395 (2006.01)
CPC (source: EP IL KR)
A61K 9/1652 (2013.01 - KR); A61K 9/2054 (2013.01 - EP KR); A61K 31/496 (2013.01 - EP IL KR); A61P 9/00 (2018.01 - EP KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022005926 A1 20220106; AU 2021299197 A1 20230202; CA 3187827 A1 20220106; CN 116234555 A 20230606; EP 4171232 A1 20230503; IL 299544 A 20230201; JP 2023531802 A 20230725; KR 20230028535 A 20230228
DOCDB simple family (application)
US 2021039303 W 20210628; AU 2021299197 A 20210628; CA 3187827 A 20210628; CN 202180051890 A 20210628; EP 21832842 A 20210628; IL 29954422 A 20221227; JP 2022581463 A 20210628; KR 20237003154 A 20210628